CLS enters the urology market in Portugal in collaboration with Avanco Advanced Medical Solutions
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announced it has entered into an exclusive distribution agreement with Avanco Advanced Medical Solutions to market and sell CLS TRANBERG® product portfolio in Portugal.
“We see a good commercial potential for the TRANBERG® Thermal Therapy System in focal laser ablation of localized prostate cancer in our market”, says Mr. Diogo Marcos, Managing Director of Avanco. “Clinicians recognize the value of being able to perform both MR fused ultrasound guided prostate biopsies and, in the case of diagnosed localized cancer, focal laser ablation of the prostate tumor with use of a common imaging and navigation platform, something CLS TRANBERG® products allows for.”
"Avanco is a long-standing partner supplying advanced medical solutions to the hospital community in Portugal and today offers state of the art solutions for MR fused ultrasound guided prostate biopsies. We see a great opportunity in Avanco expanding their product offering to also include our TRANBERG® products for MR fused ultrasound guided focal laser ablation” says Perjan Pleunis, VP Sales in Europe at CLS.
About prostate cancer
About 1,400,000 new cases per year of prostate cancer are reported worldwide with approximately 350.000 of them within EU. Although the landscape of prostate cancer treatment shows several treatment options, there is still an important unmet need for patients with localized prostate cancer who progressed to intermediate risk stage. The currently available surgical options show significant risks and side effects related to urinary and erectile functions and quality of life.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS and TRANBERG
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. All components of the TRANBERG®|Thermal Therapy Systems have received EU-wide regulatory approval as medical devices (CE-marked class II) for the treatment of soft tissue lesions. CLS is developing its systems to get CE-mark class III for disposable TRANBERG laser applicators to be used in brain as well as expanding the current CE-mark for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se
About Avanco Advanced Medical Solutions
Avanco, founded in 1936 by Nicolau Marcos, has been present in the health sector in Portugal since 2000 in commercialization of medical devices, technical assistance, user training, design of clinical units and manufacturing of radiation protection solutions. The promotion and continuous support of innovative solutions that enable quality improvement are an integral part of the company DNA. The investment in advanced technologies requires monitoring by specialized teams, available to respond immediately to all needs. For this purpose, Avanco has resources in the most diverse areas such as sales & marketing, clinical application support, diagnostic and therapeutic technical support, and electro-mechanical engineering.
For more information about Avanco, please visit the Company's website: Sociedade Avanço - Advanced Medical Systems - Portugal (ams.pt)